PMID- 32341851
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 2156-7085 (Print)
IS  - 2156-7085 (Electronic)
IS  - 2156-7085 (Linking)
VI  - 11
IP  - 4
DP  - 2020 Apr 1
TI  - Automated morphometric measurement of the retinal pigment epithelium complex and 
      choriocapillaris using swept source OCT.
PG  - 1834-1850
LID - 10.1364/BOE.385113 [doi]
AB  - We report the development of an automated method to measure morphological 
      features of the retinal pigment epithelium (RPE), Bruch's membrane (BM) and 
      choriocapillaris (CC) using a commercially available swept source OCT (SS-OCT) 
      system. The locations of the inner segment/outer segment (IS/OS), RPE and CC were 
      determined by optical coherence tomography (OCT) and OCT angiography (OCTA) 
      A-scan intensity profiles, which were used to calculate the mean IS/OS-to-RPE 
      distance, mean RPE-to-CC distance, mean RPE-to-CC outer boundary distance, mean 
      RPE thickness and mean CC thickness across the entire scan volume. The automated 
      method was tested on two groups of normal subjects: younger age group (n=20, 
      30.3 +/- 5.72 years, axial length = 24.2 +/- 0.96 mm) and older age group (n=20, 
      80.8 +/- 4.12 years, axial length = 23.5 +/- 0.93 mm). The 6x6 mm macular scans were 
      acquired from one eye of each subject. Repeatability of the measurements showed a 
      coefficient of variance < 5% for all the cases. CC locations were confirmed 
      qualitatively with pixel-by-pixel moving of the en face OCT/OCTA images. Relative 
      distance and thickness maps of the RPE-BM-CC complex were generated for 
      visualization of regional changes. We observed thinner CC, thinner RPE and 
      increased RPE-to-CC distance in the older age group. Correlation between CC 
      thickness and choroid thickness suggests that the CC thins with the overall 
      thinning of the choroid. These metrics should be useful to reveal more 
      morphological details of RPE-BM-CC complex, provide a better understanding of the 
      CC in three dimensions, and further investigate potential functional 
      relationships between RPE, BM and CC, and their involvement in age-related ocular 
      diseases.
CI  - (c) 2020 Optical Society of America under the terms of the OSA Open Access 
      Publishing Agreement.
FAU - Zhou, Hao
AU  - Zhou H
AUID- ORCID: 0000-0003-0068-5102
AD  - Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
FAU - Dai, Yining
AU  - Dai Y
AD  - Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
FAU - Gregori, Giovanni
AU  - Gregori G
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami 
      Miller School of Medicine, Miami, FL 33136, USA.
FAU - Rosenfeld, Philip R
AU  - Rosenfeld PR
AD  - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami 
      Miller School of Medicine, Miami, FL 33136, USA.
FAU - Duncan, Jacque L
AU  - Duncan JL
AD  - Department of Ophthalmology, University of California, San Francisco, CA 94143, 
      USA.
FAU - Schwartz, Daniel M
AU  - Schwartz DM
AD  - Department of Ophthalmology, University of California, San Francisco, CA 94143, 
      USA.
FAU - Wang, Ruikang K
AU  - Wang RK
AUID- ORCID: 0000-0001-5169-8822
AD  - Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
AD  - Department of Ophthalmology, University of Washington, Seattle, WA 98105, USA.
LA  - eng
GR  - P30 EY002162/EY/NEI NIH HHS/United States
GR  - R01 EY028753/EY/NEI NIH HHS/United States
PT  - Journal Article
DEP - 20200306
PL  - United States
TA  - Biomed Opt Express
JT  - Biomedical optics express
JID - 101540630
PMC - PMC7173887
COIS- Dr. Gregori, Dr. Rosenfeld and Dr. Wang received research support from Carl Zeiss 
      Meditec, Inc. Dr. Gregori and the University of Miami co-own a patent that is 
      licensed to Carl Zeiss Meditec, Inc. Dr. Rosenfeld is a consultant for Apellis, 
      Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, Ocunexus 
      Therapeutics, Hemera Biosciences, F. Hoffmann-La Roche Ltd., Isarna 
      Pharmaceuticals, Ocunexus, Ocudyne, and Unity Biotechnology. Dr. Rosenfeld has 
      equity interest in Apellis, Verana Health, and Ocudyne. Dr. Duncan is a 
      consultant for AGTC, California Institute for Regenerative Medicine, Foundation 
      Fighting Blindness, Editas Medicine, Ionis Pharmaceuticals, Novelion 
      Therapeutics, ProQR Therapeutics, SparingVision, Spark Therapeutics. Dr. Duncan 
      also receives research support from Foundation Fighting Blindness, Neurotech USA, 
      Inc. Dr. Wang discloses intellectual property owned by the Oregon Health and 
      Science University and the University of Washington. Dr. Wang also receives 
      research support from Tasso Inc, Moptim Inc, and Colgate Palmolive Company. He is 
      a consultant to Insight Photonic Solutions and Carl Zeiss Meditec. Dr. Zhou, Dr. 
      Dai and Dr. Schwartz declare no conflicts of interest.
EDAT- 2020/04/29 06:00
MHDA- 2020/04/29 06:01
PMCR- 2020/04/01
CRDT- 2020/04/29 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2020/03/01 00:00 [revised]
PHST- 2020/03/02 00:00 [accepted]
PHST- 2020/04/29 06:00 [entrez]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2020/04/29 06:01 [medline]
PHST- 2020/04/01 00:00 [pmc-release]
AID - 385113 [pii]
AID - 10.1364/BOE.385113 [doi]
PST - epublish
SO  - Biomed Opt Express. 2020 Mar 6;11(4):1834-1850. doi: 10.1364/BOE.385113. 
      eCollection 2020 Apr 1.